Skip to main content
. 2024 Nov 5;98(12):e01285-24. doi: 10.1128/jvi.01285-24

Fig 1.

Table summarizes participant demographics and vaccination status at different study stages, with graphs below depicting proportions of disease severity across different groups, vaccination statuses, and genders.

Characteristics of the four patient cohorts and the levels of COVID-19 severity during the acute disease phase. (A) Schematic representation of the study participants—including at the pre-infection, acute phase, and 3- and 5-months post-infection. The study participants were categorized based on vaccination doses. Characteristics such as sex, age, vaccination status, and underlying health conditions were documented. (B) The proportion of disease severity observed in the inactivated vaccine group compared to that in the S protein vaccine group. (C) The proportion of disease severity observed among the males and females. (D) The proportion of disease severity in the participants who had been vaccinated with zero, one, two, or three doses. The counts were analyzed using the Chi-squared test with a statistical significance level set at P < 0.05 (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; and n.s., not significant.). Un-vac, unvaccinated individuals; Vac-1, individuals who had received one dose of COVID-19 vaccine; Vac-2, individuals who had received two doses of COVID-19 vaccine; Vac-3, individuals who had received three doses of COVID-19 vaccine. I, inactivated SARS-CoV-2 vaccine; S, RBD recombinant subunit vaccine; IQR, interquartile range.